What are potential barriers and enablers to patient and physician participation in Canadian cell therapy trials for stroke? A stakeholder interview study

• Dean A Fergusson,
• Dar Dowlatshahi,
• Manoj M Lalu,
• Justin Presseau,
• Gisell Castillo,
• Madison Foster,
• Analyssa Cardenas,
• Whitney Tam,
• Jennifer Zlepnig,
• Deborah Timpson,
• Pascale Juneau

Affiliations

Dean A Fergusson

Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Dar Dowlatshahi

Department of Medicine, Division of Neurology and Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada

Manoj M Lalu

associate scientist and assistant professor

Justin Presseau

Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Gisell Castillo

Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Madison Foster

Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Analyssa Cardenas

Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Whitney Tam

Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Jennifer Zlepnig

Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada

Deborah Timpson

Department of Rehabilitation, Pembroke Regional Hospital, Pembroke, Ontario, Canada

Pascale Juneau

Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada